AstraZeneca partners with Oracle for AI-driven clinical trials

Oct 20 (Reuters) AstraZeneca said on Tuesday that it is working with Oracle to use AI and ​real-world data to identify eligible patients ‌for clinical trials and monitor safety signals, among other measures, as the drugmaker looks to improve clinical research. • The collaboration will combine ‌AstraZeneca s ​drug development expertise ⁠with Oracle s AI and ⁠healthcare data capabilities to support patient matching and research • Initial work will focus on cancer, cardiovascular, respiratory, immunology ​and rare diseases, and could also support earlier diagnosis of serious diseases • ⁠The first project will ⁠support hypertension research in Abu ​Dhabi in partnership with UAE-based healthcare firm ​M42 • Patient recruitment remains one of ‌the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs • Incorrect trial ⁠designs have also hurt AstraZeneca in the past, with delays on its breast cancer drug ⁠and ‌nerve